News

Jones offered his insights for discharging patients as well as follow-up outpatient treatment.

In our latest roundtable series, we discuss COVID-19 treatment management and prevention 4 years after the start of the pandemic.

Most outbreaks were caused by Cryptosporidium, a chlorine-resistant parasite, underscoring the need for stricter safety measures and better facility management.

The complex and often frustrating realities that patients face when dealing with a post-infection condition that remains misunderstood by many continue to unfold.

The 2 companies will examine molnupiravir (Lagevrio) using a different formulation that is not approved in any country globally.

A small study shows that 68% of these patients were given this class of medication, which highlights a disconnect between treatment guidelines and clinical practice.

Nirsevimab proves effective in preventing RSV-related medical visits and hospitalizations in infants, with enhanced results in catch-up immunization programs.

The combination therapy’s developer, Atea Pharmaceuticals, is looking to initiate a phase 3 study in early 2025.

Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.

Raw milk products are not pasteurized, making them more susceptible to carrying harmful pathogens, in this case, bird flu.

Sixty-eight people have been infected with this food borne illness across 19 states.

Daniel Ilges, PharmD, BCIDP discussed this improved diagnostic stewardship, reduced unnecessary treatments, and had no impact on diagnosis timelines.

This comes after Japan recently announced it will donate over 3 million doses of the mpox vaccine, LC16m8 to a country in Africa.

In this conversation, Jones discussed looking at the benefits around choosing 1 specific therapy for treatment.

Research finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.

This week, GigaGen has launched a Phase 1 trial for GIGA-2339, a potential functional cure for chronic Hepatitis B, public health concerns like the California raw milk recall due to H5N1 and new findings linking lung dysfunction to cognitive decline in Long COVID patients, and more.

This study explores HLA-E as a target to activate the immune system in HBV infection, identifying a stable peptide, Env371-379 L6I, that effectively triggers T-cell responses.

With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.

Mild reactions were experienced in 46% of recipients.

New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.

Recent data shows a 1 in 5 risk of unvaccinated house members transmitting the respiratory virus to other nonimmunized members.

CDPH advises consuming pasteurized milk, which kills the virus, while the state increases testing and monitoring following 29 confirmed human cases of H5N1 linked to infected dairy cows.

It is not only about cooking the food to the correct temperature, but also how long the food should sit out, and safe storage after the meal is over. Here is more information to have a healthy holiday.

Using fecal microbiota transplantation within the CGA framework further enhanced survival and care efficiency.

This bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for the concerns around infective endocarditis and when choosing empiric therapy.

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.